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Background. Amnestic Mild Cognitive Impairment (aMCI) is considered a transition 
stage between normal aging and Alzheimer's disease (AD). Two main clinical subtypes 
of aMCI have been identified: 1) aMCI single domain (aMCI-SD), with isolated episodic 
memory impairments, and 2) aMCI multiple domain (aMCI-MD), with episodic memory 
impairments and deficits in one or more other cognitive domains.  
Aims.To map the pattern of gray matter (GM) atrophy associated with aMCI-SD, aMCI-
MD and mild AD. 
Methods. A group of aMCI-SD, aMCI-MD characterized by executive function disorders, 
mild AD patients and cognitively unimpaired age-matched subjects underwent a 
comprehensive neuropsychological assessment and a high-definition MR brain scan. 
Voxel-based morphometry (VBM) analysis was used to characterize the GM tissue loss 
in each patient group, and the common pattern of GM atrophy in aMCI-SD and aMCI-
MD.  
Results. The results revealed that aMCI-SD and aMCI-MD are characterized by a 
common pattern of GM atrophy within the medial temporal cortex, predisposing to AD 
and correlating with the severity of verbal memory symptoms. Moreover, the pattern of 
GM atrophy observed in aMCI-SD, aMCI-MD and mild AD revealed that, from an 
anatomical point of view, these three clinical syndromes could represent three severity 
points along the continuum between normal aging and AD.  
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Alzheimer’s disease (AD) is a neurodegenerative disorder that progressively disrupts 
patients’ cognitive capacities. Although it is widely accepted that episodic memory 
impairment is the clinical hallmark of AD in the majority of cases [1] (for a review see 
[2]), deficits of executive functions [3, 4], semantic memory [5-8], and visuospatial 
abilities [9] have also been reported at the very early stages of the disease.  From a 
neuropathological point of view, it has been suggested that the medial temporal cortex is 
the anatomical site of the first pathological alterations in AD [10, 11]. In fact, the 
neurofibrillatory pathology, highly correlated with neural and synapsis loss [12], would 
begin to compromise these regions years or even decades before the diagnosis of AD, 
when the disease is still considered ‘clinically silent’ [10]. The neuropathology would 
then spread through the limbic cortex and finally, at more advanced stages of the disease, 
to the isocortical association regions [10, 11].   
Over the last 10-15 years, clinical research has focused on what is considered the 
preclinical phase of AD, i.e. the Mild Cognitive Impairment (MCI). MCI is defined as a 
cognitive decline greater than expected for an individual’s age and education level but 
that does not interfere notably with activities of daily life [13, 14]. Amnestic MCI (aMCI) 
is characterized by memory complaints and deficits have been consistently shown to be at 
high risk of progressing towards AD. In fact, about 10-15% of aMCI convert to AD 
yearly, a rate that is five times greater than that of healthy elders [14-17]. In aMCI, poor 
performance in delayed recall tests, as revealed by formal neuropsychological assessment 
[18-20], and brain damage (brain tissue loss and/or hypoperfusion) in the medial 
temporal regions [21-25] are considered key prognostic indicators of progression to AD.   
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Two main clinical subtypes of aMCI have been identified: 1) single domain aMCI 
(aMCI-SD), when memory is the only domain impaired, and 2) multiple domain aMCI 
variant (aMCI-MD), when besides the memory deficit, at least another cognitive domain 
is impaired (e.g. executive function, language, or visuo-spatial skills) [26]. It has been 
suggested that these two aMCI subtypes not only differ in their clinical manifestations, 
but that they are also associated with different outcomes. In fact, the rate of conversion to 
AD is considerably greater when memory deficits are associated with other cognitive 
deficits than when they are isolated [27], suggesting that aMCI-MD may represent a more 
advanced prodromal stage of AD. However, at present, it is not known whether single 
and multiple domain aMCI reflect different degrees of impairment along a continuum 
towards AD.  
In the present study, we address this issue from an anatomical point of view by 
delineating the pattern of gray matter (GM) atrophy in aMCI single domain (aMCI-SD), 
aMCI multiple domain (aMCI-MD) and mild Alzheimer’s disease patients, by means of 
voxel-based morphometry technique. In order to minimize the clinical heterogeneity of 
our participant samples, only aMCI-MD subjects presenting an executive function deficit 
associated with the memory impairment were included in the study.  If aMCI-SD and 
aMCI-MD represent two different severity stages on the continuum between normal 
aging and mild AD, we expect that: 1) they share a common pattern of GM atrophy 
reflecting the same underlying neuropathological mechanisms predisposing to AD; 2) 
The pattern of atrophy of each group of patients at a more ‘advanced stage’ of the disease 







Participants were selected from a pool of patients fulfilling clinical criteria for 
Alzheimer’s disease (AD) or Mild Cognitive Impairment (MCI) recruited at the 
Alzheimer and Related Disorders Clinic of the McGill centre for studies in aging 
(MCSA) and at the Cognition Clinique of the Institut Universitaire de Gériatrie de 
Montréal. AD patients met the Diagnostic and Statistical Manual for Mental Disorders-IV 
[28] clinical criteria and the NINCDS-ADRDA research criteria for probable AD [29]. 
Only patients mild-AD, defined as those with a MMSE score [30] ≤ 24 and ≥18, were 
included in the study. 
MCI met Petersen’s criteria [13]. According to the criteria, MCI showed (1) a cognitive 
complaint corroborated by an informant; (2) objective memory deficit (see below); (3) 
normal global functional level, as measured by a Mini-Mental Mental State Examination 
score ≥ 25 [30]; (4) no significant impact on normal daily activities, as assessed by the 
Functional Autonomy Measurement System (SMAF) or Instrumental Activities of Daily 
Living (IADL) scale and a clinical interview.   
Amnestic MCI were classified into two subgroups, a subgroup of single domain amnestic 
MCI (aMCI-SD) and a subgroup of multiple domain amnestic MCI (aMCI-MD). aMCI-
SD patients were identified based on the presence of an isolated memory impairment, as 
revealed by impaired performance (1.5 standard deviations below the average of age- and 
sex-matched healthy subjects) on at least one of the standard memory tests employed in 
the neuropsychological battery described below.  In order to minimize the clinical 
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heterogeneity, only executive aMCI-MD subjects were included in the study. aMCI-MD 
patients were selected based on the presence of an executive function deficit 
accompanying the memory impairment. The executive function deficit was defined on 
the basis of a performance at least 1.5 standard deviations below normative values in the 
Stroop-Victoria test – 3
rd
 plate subtest (see ‘Neuropsychological Battery’ section). MCI 
individuals without memory deficits (non-amnestic MCI) were not included in the study.   
A total of 35 patients were included in the study. Of these, ten met criteria for mild AD 
(age= 71.5±5.9, M/F=5/5), 11 for aMCI-SD (age= 74.9±7.7, M/F=5/6) and 14 for aMCI-
MD (age= 72.3±6.2, M/F=3/11).  
Even though all patients underwent a high definition brain MRI scan, diagnosis was made 
blind to MRI images. Both AD and aMCI had a complete neurological and medical 
examination to exclude other neurological diseases or other factors that could account for 
their condition.   
A group of 13 cognitively unimpaired individuals (normal controls - NC) (age= 75.0±5.1, 
M/F=5/8), as assessed by a neuropsychological screening battery, was recruited from the 
same community of AD and MCI patients (Table 1). Normal controls were matched by 
age, sex and education to AD and MCI patients. Exclusion criteria for all participants 
(both patients and healthy controls) included history of systemic or neurological disease 
(including cerebrovascular disease), past or current psychiatric illness, traumatic brain 
injury, former intracranial surgery, history of alcoholism or drug abuse, untreated medical 
or metabolic condition, general anesthesia in the last 12 months, and uncorrected hearing 
and vision problems. 
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The study was approved by the ethics committee on human research of the Centre de 
Recherche de l’Institut Universitaire de Gériatrie de Montréal (CRIUGM). All 
participants provided written informed consent before taking part in the study.  
Neuropsychological Screening Assessment 
Both patients and controls underwent a battery of standard tests in order to assess their 
neuropsychological profile.  General functional level was measured by means of the Mini 
Mental State Examination (MMSE) [30].  Verbal and visuo-spatial episodic memory 
were assessed with the Test de rappel libre/rappel indicé à 16 items (RL/RI-16), a 
commonly-used verbal test of free and cued recall in French-speaking populations [31, 
32] and the immediate and delayed recall of Rey Complex Figure [33], respectively. 
Executive functions were tested by means of the Stroop-Victoria test [34], more 
specifically the subtest where subjects are asked to name the color of words written in 
different color ink (the Stroop-Victoria test – 3
rd
 plate). Visuospatial abilities were 
evaluated using the copy of the Rey Complex Figure [33] and the Benton Line orientation 
Test [35], while semantic abilities were assessed using the 15-item version of the Boston 
Naming Test, BNT [36]. 
Statistical Analysis 
A one-way ANOVA statistical analysis was carried out in order to assess for significant 
differences in each test score between the different groups.  Specifically, the test score 
was entered in the model as dependent variable and the ‘group’ as four-level factor (NC, 
aMCI-SD, aMCI-MD, mild AD).  For each test revealing significant differences among 
groups, post hoc pair-wise comparisons were performed using Tukey’s method. 
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All statistical analyses were performed using SPSS 16.0 software package for Windows 
(release 16.0.0, SPSS Inc., Chicago, IL). 
Voxel-Based Morphometry Analysis 
Image Acquisition 
MRI images were obtained on a 3T Siemens Trio MRI (Siemens, Erlangen, Germany) at 
the Unité de neuroimagerie fonctionnelle (UNF) of the Institut Universitaire de Gériatrie 
de Montréal (www.unf-montreal.ca). A volumetric magnetization prepared rapid gradient 
echo (MPRAGE) sequence was used to acquire high resolution T1-weighted 3D 
anatomical images, using the following parameters: TR = 2.3 sec, TE = 2.91 ms, TI = 900 
ms, flip angle =9°, FOV = 240 x 256, voxel size = 1x1x1.2 mm
3
, 8-channel coil. Images 
were acquired in the horizontal plane, along the length of the hippocampal axis.  
Voxel-Based Morphometry analysis 
Voxel-Based Morphometry (VBM) analysis included two steps: spatial preprocessing 
(normalization, segmentation, Jacobian modulation and smoothing) and statistical 
analysis.  Both steps were implemented in the SPM5 software package (Wellcome 
Department of Imaging Neuroscience, London; http://www.fil.ion.ucl.ac.uk/spm) running 
on Matlab 6.5.1 (MathWorks, Natick, MA).  
Anatomical MRI images were spatially pre-processed using standard procedures [37].  
All T1 structural images were segmented, bias corrected and spatially normalized to 
Montreal Neurological Institute (MNI) space using the unified segmentation procedure 
[38]. The VBM analysis was based on modulated gray matter images, whereby the gray 
matter value in each voxel is multiplied by the Jacobian determinant derived from the 
spatial normalization in order to preserve the total amount of gray matter from the 
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original images. These modulated gray matter images were smoothed with a Gaussian 
kernel (8 mm FWHM). 
In order to test for GM volume difference among subject groups, a full-factorial ANOVA 
statistical design was employed entering the GM smoothed images as dependent variable, 
the group as a four-level factor, and sex and age as confounding covariates.  In order to 
test for significant regional differences that cannot be ascribed to changes in total GM 
volume, a proportional scaling model was used.   
Gray matter volume differences between patients and controls were assessed using the 
General Linear Model [39] and the significance of each effect was determined using the 
theory of Gaussian fields [40].  Specific statistical contrasts were set in order to identify 
the brain regions showing:  
- Common GM atrophy in aMCI-SD and aMCI-MD (aMCI-MD vs. NC inclusively 
masked for the contrast aMCI-SD vs. NC at a threshold of p<0.005); 
- GM atrophy in aMCI-SD, aMCI-MD and mildAD compared to normal controls (aMCI-
SD vs. NC; aMCI-MD vs. NC; mildAD vs. NC). 
When the whole-brain was explored, a threshold of significance of p<0.001 uncorrected 
was accepted.  Within our a priori regions of interests (ROIs) based on previous 
neuroanatomical studies [10, 11, 24, 41], incuding temporal and frontal brain regions, a 
less conservative threshold of p<0.005 uncorrected was employed. The ROIs, including 
the bilateral temporal lobes, were drawn using the Anatomical Automatic Labeling brain 
atlas [42] and were applied to the SPM dataset by means of the Wake Forest University 





Neuropsychological Screening Assessment (Table 1) 
The one-way ANOVA revealed a group effect for all tests included in our 
neuropsychological battery.  As revealed by the Tukey’s post-hoc analyses, the group 
effect was largely driven by the AD group for the majority of tests.  AD subjects showed 
a lower performance than NC in all tests except for the Benton Line Orientation Test. 
Moreover, AD scores were lower than aMCI-SD in the Rey-Osterrieth Figure Recall 
subtests, the RL/RI-16 recall subtests, and in the Stroop-Victoria 3
rd
 plate, and AD scores 
were lower than aMCI-MD in RL/RI-16 delayed and total free recall subtests and in the 
Stroop-Victoria 3
rd
 plate (time).  Both aMCI subgroups showed lower performance than 
NC in the verbal memory test, but only aMCI-MD revealed significant differences in the 
recall subtests of the Rey Complex Figure.  
Consistently with our inclusion criteria, aMCI-MD showed a lower performance in the 
executive function ability score (Stroop-Victoria 3
rd
 plate - number of errors) when 
compared to aMCI-SD. No significant differences were observed in other tests of the 
neuropsychological screening battery between aMCI-SD and aMCI-MD, although a trend 
towards significance was observed in tests assessing visuo-spatial memory (Figure 1).  
 
Voxel-Based Morphometry  
Pattern of common GM atrophy in aMCI-SD and aMCI-MD (Figure 2) 
We observed a common pattern of GM atrophy in aMCI-SD and aMCI-MD confined to 
the left enthorinal cortex (x= -11, y= 10, z= -40, Z-score= 3.7, p<0.001 uncorrected) 
(Figure 2).  
11 
 
Post-hoc correlation analysis between left medial temporal cortex atrophy and cognitive 
scores 
A post-hoc correlation analysis was performed in order to test the hypothesis of an 
association between the GM volume in the left medial temporal cortex and the 
performance in memory tests in the aMCI cohort. For each participant, the value of GM 
volume was extracted from a 6-mm radius sphere centered on peak of common atrophy in 
aMCI-SD and aMCI-MD (x= -11, y= 10, z= -40) by means of SPM5 software. A 
bivariate correlation statistical analysis was then run using SPSS statistical package in 
order to test the association between GM volume and the score in each test included in 
the neuropsychological assessment. The results showed a significant positive correlation 
between the GM volume in this area and the performance in tests assessing verbal 
memory (RL/RI-16: Delayed Free Recall, r=0.40, p<0.05; Delayed Total Recall, r=0.43, 
p<0.05), but not in tests assessing visuo-spatial memory (Rey Complex Figure: 3 min 
recall, r=0.30, p=0.15; 20 min recall, r=0.28, p=0.18) and semantic memory (Boston 
Naming Test, r=0.23, p=0.26), visuo-spatial (Rey Complex Figure copy: r=-0.01, p=0.94; 
Benton Line Orientation: r=-0.29, p=0.16) and executive function abilities (Stroop-
Victoria Test: 3rd plate errors, r=-0.28, p=0.17; 3rd plate time (sec), r=-0.01, p=0.95). 
        
Pattern of GM atrophy in aMCI-SD, aMCI-MD and mild AD (Table 2 and Figure 3) 
aMCI-SD vs. NC 
When compared to normal controls, aMCI-SD showed a pattern of GM atrophy mainly 
confined to the left medial temporal cortex, including the medial temporal lobe and the 
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left enthorinal cortex, and the bilateral superior frontal gyrus. At the subcortical level, 
brain areas of atrophy were also found bilaterally in the thalamus.  
aMCI-MD vs. NC 
When compared to normal controls, aMCI-MD showed a pattern of GM atrophy that 
included all regions that were found to be atrophic in the comparison between aMCI-SD 
and normal controls.  In addition to what was observed in  aMCI-SD, the aMCI-MD 
group showed a more extensive pattern of atrophy involving brain areas such as the 
lateral temporal cortex that were not damaged in the aMCI-SD sample. Specifically, 
aMCI-MD showed GM loss bilaterally in the inferior temporal regions, including the 
bilateral temporal gyri and the right fusiform gyrus, and in the anterior portion of the left 
superior temporal gyrus.   
Mild AD vs. NC 
When compared to normal controls, mild AD showed a pattern of GM atrophy that 
included all regions that were found to be atrophic in the comparison between aMCI-MD 
and normal controls.  However, in addition to what was observed in aMCI-MD, the 
comparison between mild AD and normal controls revealed areas of GM atrophy in the 
right medial temporal cortex (medial temporal lobe and enthorinal cortex) spreading to 
the hippocampus and amygdala. The atrophy in the lateral temporal lobes also involved 
posterior regions of the left middle temporal gyrus and the right temporal pole. Within 
the frontal lobe, GM volume loss was observed in the left inferior frontal gyrus pars 
opercolaris, in addition to the bilateral superior frontal gyri, already found to be atrophic 





In the present study, we aimed to identify the pattern of gray matter (GM) atrophy in 
patients with amnestic MCI single (aMCI-SD) and multiple domain (aMCI-MD) and 
mild AD. Our VBM anatomical results showed that: 1) aMCI-SD and aMCI-MD 
individuals share a common pattern of anatomical alterations within the medial temporal 
cortex predisposing to AD and revealing the common nature of these conditions; 2) the 
GM volume in this regions correlates with verbal memory scores, revealing the 
anatomical counterpart of the memory deficit observed in the neuropsychological 
evaluation; 3) from an anatomical point of view, we observed that aMCI-MD represents a 
transition stage between aMCI-SD and mild AD.  
 
aMCI sample characterization 
Amnestic MCI individuals were here classified as single domain (aMCI-SD) when the 
episodic memory impairment was isolated and as multiple domains when it was 
associated with an executive function deficit (aMCI-MD). Based on our inclusion 
criteria, 11 out of 25 aMCI (44%) were labeled as single domain, while 14 out of 25 
(56%) as aMCI-MD, consistently with previous studies reporting that isolated memory 
impairments are generally less common than multiple cognitive domain deficits [25, 44, 
45].  
Overall, the neuropsychological assessment did not reveal significant score differences 
between aMCI-SD and aMCI-MD in any of the memory tests included in the 
neuropsychological screening battery. However, aMCI-MD showed a trend for lower 
performance in visuo-spatial memory tests, approaching the level of statistical 
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significance. This result could indicate that aMCI-MD do not only differ from aMCI-SD 
in the presence of a cognitive deficit associated with the memory impairment, but also in 
the severity of the memory deficit. A pattern of more severe memory deficit in aMCI-MD 
compared to aMCI-SD would provide support to the hypothesis that, from a 
neuropsychological point of view, aMCI-SD and aMCI-MD are two severity stages on 
the same continuum rather than two separate clinical syndromes. However, further 
neuropsychological studies aimed at better characterizing the nature of memory deficits 
in larger samples of aMCI-SD and aMCI-MD and follow-up data are necessary to 
confirm this hypothesis.  
 
Common atrophy in aMCI-SD and aMCI-MD 
The analysis of the common atrophy in aMCI-SD and aMCI-MD revealed that the two 
clinical subgroups share a common pattern of GM loss involving the left enthorinal 
cortex. The enthorinal together with the transenthorinal cortex have been identified as the 
anatomical sites of the first pathological alterations in AD [10, 11], that are believed to 
occur years before the dementia syndrome develops [10]. In previous anatomical studies, 
gray matter tissue loss in the antero-medial temporal lobe was observed in individuals 
with aMCI [45-48], who are considered to be in the prodromal stage of AD, but only in a 
small percentage of non amnestic MCI [25] who are considered at lower risk of 
progressing to AD. As a matter of fact, the presence of medial temporal atrophy can 
successfully predict the clinical progression to AD in individuals with MCI [22-25]. 
Here, for the first time, we showed that the atrophy in the antero-medial temporal cortex 
not only characterizes different clinical subtypes of aMCI, at high risk of progressing to 
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AD, but also that the degree of atrophy is significantly associated with the severity of the 
memory symptoms. Taken together, these data suggest that an in-depth evaluation of 
memory abilities and of anatomical features could represent valuable tools to identify 
aMCI individuals at risk of converting to AD. Moreover, these findings suggest that 
aMCI-SD and aMCI-MD may share a common underlying pathology, rather than 
reflecting two separate clinical entities.  
  
Pattern of GM atrophy in aMCI-SD, aMCI-MD and mild AD 
As predicted by the hypothesis that aMCI-SD, aMCI-MD and mild AD could represent 
three different severity points on the same continuum, the brain regions found to be 
atrophied in the more advanced stages involved the same brain regions found to be 
atrophied in the earlier stages. Specifically, the three clinical groups revealed a pattern of 
GM atrophy spreading from medial temporal areas to the limbic system at earlier stages 
and then to the associative areas of the neo-cortex at more advanced stages. 
Medial temporal regions are more severely and more extensively atrophic in the left-
hemisphere in aMCI-SD. A more severe degree of atrophy in the left compared to the 
right medio-temporal cortex has been previously reported in AD patients [49, 50]. This 
left-lateralized effect observed in anatomical studies may reflect a recruitment bias and 
may be influenced by the differential symptoms associated with the left and right medio-
temporal atrophy. In fact, it is possible that aMCI individuals characterized by early 
visuo-spatial memory symptoms associated with right medio-temporal cortex atrophy 
rarely present at a neurology clinic; therefore they are less likely to be classified as aMCI 
early. These patients may consult their physician at later stages of the neurodegenerative 
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course, when more verbal aspects of the memory impairment (associated with left medio-
temporal cortex atrophy) emerge and when the memory deficit becomes more evident. 
aMCI-MD individuals, who were characterized by executive function deficits based on 
our inclusion criteria, did not show more severe atrophy in frontal areas compared to 
aMCI-SD as expected. This could be explained by the fact that early executive function 
deficits in aMCI-MD may result from a disconnection between anterior and posterior 
cortical areas before subsequent atrophy in the prefrontal cortex can be detected, as 
previously proposed [51].  
It must be noted that the anatomic results could be influenced by the fact that the aMCI-
MD cohort includes more individuals with incipient AD compared to the aMCI-SD. In 
fact, longitudinal studies have shown that aMCI-MD have a greater risk of progressing 
towards AD than patients with single domain aMCI-SD [26]. Further studies with 
longitudinal follow-up should be performed in order to confirm this result.  
 
Taken together, our findings suggest that aMCI-SD and aMCI-MD represent two degrees 
of severity along a continuum between normal aging and AD, rather than reflecting two 
separate clinical syndromes resulting from different etiological factors. Even if we are not 
allow to draw conclusions on the pathology based on GM atrophy data, the pattern of GM 
atrophy observed in aMCI-SD, aMCI-MD and mild AD when compared to healthy 
controls seems to mirror the different neuropathological stages of Alzheimer’s related 
changes described by Braak and colleagues [10, 11], with GM atrophy spreading from 
medial temporal areas to the limbic system at earlier stages and then to the associative 
areas of the neo-cortex at more advanced stages. In this context, aMCI-SD individuals 
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deserve particular attention for early intervention.  Identifying the prodromal stages of 
AD may in fact allow us – once a specific treatment has become available – to slow down 
the neurodegenerative process before developing full-blown dementia.   
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Figure 2. Pattern of common atrophy in aMCI-SD and aMCI-MD (aMCI-MD vs. NC 
inclusively masked for the contrast aMCI-SD vs. NC). The results are superimposed to a 
coronal (left) and axial (right) slice of a canonical T1 template. The coordinates reported 
below the brain sections correspond to the position of the slices within the MNI 
stereotaxic space.  
 




Figure 3. VBM results superimposed to the 3-D rendering of the standard MNI brain 
without cerebellum showing the involvement of the temporal regions in aMCI-SD 
(green), aMCI-MD (yellow) and mild AD (light blue) compared to the control group.  
 
 


















Demographics      
Age (years) F(3,44)=0.9 75.0 (5.0) 74.9 (7.7) 72.3 (6.2) 71.5 (5.9) 
Education (years) F(3,44)=0.6 14.9 (5.0) 13.6 (3.6) 12.9 (5.2) 12.6 (4.7) 
Gender (M/F) χ²=2.5 5/8 5/6 3/11 5/5 
General Functional Level      
MMSE  F(3,43)=35.3* 29.1 (1.2) 28.5 (1.0) 26.5 (1.8)
a,c 22.5 (2.3)a,b,c 
Neuropsychological Assessment      
Rey Complex  Figure (max=36)       
   Copy  F(3,44)=3.6* 33.1 (2.3) 29.5 (3.6) 28.6 (3.0)
a 27.9 (7.4)a 
   Immediate Recall 3 min  F(3,44)= 14.0* 18.1 (6.2) 11.9 (6.3)
a 8.5 (5.0)a 4.5 (2.6)a,b 
   Delayed Recall 20 min F(3,42)=14.4* 17.5 (5.6) 12.2 (6.0) 8.2 (4.4)
a 4.3 (2.3)a,b 
RL/RI-16 (max=16)      
   Immediate free recall F(3,43)=14.8* 8.7 (2.5) 5.5 (1.7)
a 4.9 (2.0)a 3.3 (1.2)a 
   Immediate total recall F(3,43)=13.8* 15.1 (0.8) 11.9 (2.5
 )a 11.1 (3.4)a 8.3 (2.4)a,c 
   Delayed free recall F(3,43)=21.9* 12.2 (2.0) 7.0 (2.3)
a 6.4 (3.9)a 2.2 (2.9)a,b,c 
   Delayed total recall F(3,43)=19.2* 15.7 (0.6) 13.3 (2.8) 11.9 (3.1)
a 6.9 (3.7)a,b,c 
Stroop-Victoria Test      
   3
rd
 plate errors F(3,42)=5.5* 1.3 (1.1) 1.0 (1.0) 3.3 (2.0)
b 4.1 (3.9)a,b 
   3
rd
 plate time (sec) F(3,42)=8.9* 27.9 (7.3) 30.6 (8.6) 43.8 (12.7) 73.4 (46.5)
a,b,c 
BNT (max=15) F(3,44)=4.0* 13.8 (1.3) 12.3 (2.1) 12.0 (2.1) 11.2 (2.9)
a 
Benton Line Orientation (max=30) F(3,35)=3.1 24.5 (3.1) 24.1 (4.1) 21.4 (3.1) 21.1 (3.2) 
 
Overall ANOVA: 
* p<0.05 across all groups 
Post-hoc pair-wise comparisons using Tukey’s method: 
a p<0.05 vs. NC; b p<0.05 vs. aMCI-SD; c p<0.05 vs. aMCI-MD 
 
Scores are reported as mean score (standard deviation).  
Abbreviations: MMSE = Mini-mental state examination; RL/RI-16= rappel libre/rappel indicé à 16 items; 











 aMCI-SD vs. NC aMCI-MD vs. NC MildAD vs. NC 
Brain Region (BA) x y z Z 
score 
x y z Z 
score 
x y z Z 
score 
Medial Temporal Cortex             
L Medial Temporal Pole 
(35/36)  
-21 8 -38 2.9 -11 10 -40 3.7 -19 11 -40 2.6 
L Entorhinal Cortex -18 2 -37 3.1 -14 9 -37 3.7 -19 8 -37 2.6 
R Medial Temporal Pole 
(35/36) 
        44 8 -31 2.6 
R Entorhinal Cortex          28 -9 -36 2.9 
             
 Limbic System             
L Thalamus -7 -5 -1 3.2 -3 -7 -1 4.0 -5 -6 -1  3.4 
R Thalamus 6 -5 -3 3.2 3 6 3 3.2 5 -8 -1 3.2 
R 
Amygdala/Hippocampus 
        25 -2 -26 3.1 
         22 -7 -34 2.8 
             
Lateral Temporal Cortex             
L Middle Temporal 
Gyrus (21), anterior 
portion 
    -42 4 -18 3.0 -50 1 -35 2.6 
                                                    
posterior portion 
       -69 -39 2 3.2 
L Inferior Temporal 
Gyrus (20) 
    -48  -28 -33 3.6 -50 -26 -33 4.0 
L Temporal Pole (38)               
R Middle Temporal 
Gyrus (21) 
        54 -3 -25 3.3 
         63 -17 -6 2.7 
R Inferior Temporal 
Gyrus (20/37) 
    48 -29 -32 2.9 53 -19 -36 3.3 
     58 -34 -29 2.9 58 -25 -29 3.4 
R Fusiform Gyrus (20)     46 -31 -31 2.8 44 -23 -35 4.0 
R Temporal Pole (38)         37 6 -24 3.8 
             
Frontal Cortex             
L Superior Frontal 
Gyrus (10) 
-19 58 17 3.6 -29 66 -9 3.0 -19 58 17 3.6 
L Inferior Frontal 
Gyrus (44) - Pars 
Opercolaris  
        -51 6 25 3.5 
R Superior Frontal 
Girus (10) 
17 61 15 2.9 21 66 1 2.9 17 61 15 3.1 
